Premium
Thalidomide and dexamethasone for resistant multiple myeloma
Author(s) -
Anagnostopoulos Athanasios,
Weber Donna,
Rankin Kim,
Delasalle Kay,
Alexanian Raymond
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04345.x
Subject(s) - thalidomide , dexamethasone , medicine , multiple myeloma , surgery , deep vein , gastroenterology , thrombosis
Summary. Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high‐dose dexamethasone‐based therapies. Remission was observed in 22 patients (47%), including six patients with complete remission. Side‐effects were frequent, mild and usually reversible, but deep vein thrombosis occurred in 8% of patients. Survival and remission times were longer among patients treated for previous resistant disease rather than for resistant relapse. This experience supports the use of thalidomide–dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients.